After signing up, you'll start to receive regular news updates from us.
Illumina Expands Services Agreement with GSK
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has announced that it has expanded the scope of its multi-year, genotyping services agreement with GlaxoSmithKline.
Under the terms of the agreement, Illumina will begin to use Sentrix® HumanHap550 BeadChips for a series of whole-genome association studies for GSK.
The study involves genotyping a collection of 2,000 case and control DNA samples provided by GSK for a specific disease, detail for which was not provided.
According to Jay Flatley, Illumina President and CEO, "We're very pleased to deepen our longstanding relationship with GlaxoSmithKline."
"This agreement underscores the increasing rate at which pharmaceutical and biotech firms are adopting genotyping technology for discovery and pharmacogenomic applications."
